News coverage about Exelixis (NASDAQ:EXEL) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exelixis earned a news impact score of 0.22 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.3079850816629 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Exelixis Slides Despite Positive Late-Stage Results (feedproxy.google.com)
- Oppenheimer Reaffirms Hold Rating for Exelixis (EXEL) (americanbankingnews.com)
- Diplomat Pharmacy begins distribution of Exelixis’ Cabometyx to treat patients with advanced RCC (pharmabiz.com)
- Exelixis, Ipsen Report Positive Results on Lead Cancer Drug (finance.yahoo.com)
- Exelixis, Ipsen report cancer drug success in late-stage study (seekingalpha.com)
Several research firms have issued reports on EXEL. Cann reaffirmed a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. Oppenheimer reissued a “hold” rating on shares of Exelixis in a research report on Wednesday. Leerink Swann cut shares of Exelixis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $34.00 to $28.00 in a research report on Friday, September 22nd. SunTrust Banks raised their target price on shares of Exelixis from $32.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $26.00 target price on shares of Exelixis in a research report on Tuesday, October 17th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Exelixis has an average rating of “Buy” and a consensus target price of $32.13.
Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.18. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The business had revenue of $152.50 million for the quarter, compared to analysts’ expectations of $104.91 million. During the same period last year, the company earned ($0.04) earnings per share. The company’s quarterly revenue was up 145.2% on a year-over-year basis. sell-side analysts anticipate that Exelixis will post 0.49 earnings per share for the current year.
In related news, Director Alan M. Garber sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total value of $454,500.00. Following the transaction, the director now owns 64,829 shares in the company, valued at $1,964,318.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Exelixis (EXEL) Receiving Somewhat Favorable Press Coverage, Report Shows” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2018/01/17/exelixis-exel-receiving-somewhat-favorable-press-coverage-report-shows.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.